Oral Mucositis Global Market Report 2025

Oral mucositis is a condition characterized by inflammation and ulceration of the mucous membranes lining the mouth. It commonly occurs as a side effect of cancer treatments, particularly chemotherapy and radiation therapy, which damage the rapidly dividing cells of the oral mucosa.

The primary indications for oral mucositis include chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Chemotherapy-induced oral mucositis arises when chemotherapy drugs damage the rapidly dividing cells in the mouth's lining, leading to painful ulcers and inflammation. Available products come in solid and liquid dosage forms, with treatment options including palifermin, amifostine, chlorhexidine, sucralfate, avasopasem, and dusquetide. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, such as hospitals, dental clinics, oncology hospitals, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The oral mucositis market research report is one of a series of new reports from The Business Research Company that provides oral mucositis market statistics, including the oral mucositis industry's global market size, regional shares, competitors with an oral mucositis market share, detailed oral mucositis market segments, market trends and opportunities, and any further data you may need to thrive in the oral mucositis industry. This oral mucositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral mucositis market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increase in cancer cases, rise in chemotherapy and radiation treatments, growth in awareness of oral mucositis, increase in adoption of supportive care therapies, higher incidence of head and neck cancers, rise in research and development in oncology supportive care.

The oral mucositis market size is expected to see strong growth in the next few years. It will grow to $2.06 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing global cancer incidence, increasing demand for personalized medicine, rising focus on palliative care, improved patient awareness and education, growing adoption of over-the-counter oral care products, increasing government and healthcare investments, and rising prevalence of radiation and chemotherapy treatments. Major trends in the forecast period include advancements in low-level laser therapy, development of novel drug delivery systems, integration of digital health technologies, adoption of artificial intelligence in treatment planning, development of tissue engineering and regenerative therapies, and advancements in smart mouthwashes and oral care products.

The forecast of 7.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer centers' ability to provide barrier-forming oral gels and low-level laser therapy devices by inflating prices of hyaluronic acid-based products developed in Italy and Israel, resulting in worse chemotherapy side effects and higher supportive oncology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of cancer is expected to drive the expansion of the oral mucositis market in the coming years. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can invade and destroy normal tissues. Several factors contribute to the increasing number of cancer cases, including an aging population, lifestyle changes, environmental exposure, infections, and genetic predisposition. Oral mucositis therapy plays a crucial role in supporting cancer patients by alleviating pain, reducing inflammation, preventing secondary infections, and promoting the faster healing of oral tissues. This ultimately enhances their comfort, nutritional intake, and overall quality of life during chemotherapy or radiation therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022. Projections indicate that these figures could rise to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the increasing prevalence of cancer is fueling the growth of the oral mucositis market.

Leading companies in the oral mucositis market are focusing on innovative treatment solutions, such as cryotherapy, to reduce the severity and incidence of the condition by using cold therapy to minimize damage to oral tissues. Cryotherapy is a medical treatment that utilizes extreme cold to freeze and eliminate abnormal or diseased tissue and is commonly used to treat conditions such as warts, tumors, or injuries. For instance, in February 2024, Chemo Mouthpiece LLC, a US-based medical device company, announced that its chemo mouthpiece device received approval from the Food and Drug Administration, a US-based government agency. This intraoral ice pack delivers cryotherapy to the oral cavity of chemotherapy patients, proactively managing and treating oral mucositis, a frequent and painful side effect of cancer treatment.

In July 2022, Solasia Pharma K.K., a Japan-based biotechnology company, acquired the episil oral liquid business from Camurus AB for an undisclosed amount. This acquisition aims to strengthen Solasia Pharma K.K.'s oncology and supportive care portfolio by leveraging Camurus AB's proprietary drug delivery technologies and innovative treatments. The deal enhances Solasia Pharma K.K.'s ability to develop and commercialize advanced therapeutics for cancer patients. Camurus AB is a Sweden-based company specializing in oral mucositis drugs.

Major players in the oral mucositis market are Merck & Co Inc., Amgen Inc., Mundipharma International Limited, Swedish Orphan Biovitrum, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, Oragenics Inc., Soligenix Inc., Jaguar Health Inc., Monopar Therapeutics Inc., EpicentRx, BrainCool, Cellceutix Corporation, GlycoMira Therapeutics Inc., Innovation Pharmaceuticals Inc., Allander Biotechnologies, Aurora BioScience, Solasia Pharma KK, NeoMedLight, MuReva (Lumitex), Prothex Pharmaceuticals Inc.

North America was the largest region in the oral mucositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral mucositis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral mucositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral mucositis market consists of revenues earned by entities by providing services such as low-level laser therapy, nutritional support, and cryotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis market also includes sales of mouthwashes and rinses, gels, sprays, or films, topical analgesics and anesthetics, and anti-inflammatory agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Mucositis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral mucositis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral mucositis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral mucositis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Chemotherapy; Radiotherapy; Hematopoietic Stem Cell Transplantation
• 2) By Product Type: Solid Dosage Form; Liquid Dosage Form
• 3) By Treatment: Palifermin; Amifostine; Chlorhexidine; Sucralfate; Avasopasem; Dusquetide
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End User: Hospitals; Dental Clinics; Oncology Hospitals; Research Institutes
• Subsegments:
• 1) By Chemotherapy: High-Dose Chemotherapy-Induced Oral Mucositis; Standard-Dose Chemotherapy-Induced Oral Mucositis
• 2) By Radiotherapy: Head And Neck Cancer Radiotherapy-Induced Oral Mucositis; Total Body Irradiation-Induced Oral Mucositis
• 3) By Hematopoietic Stem Cell Transplantation: Autologous Stem Cell Transplantation-Induced Oral Mucositis; Allogeneic Stem Cell Transplantation-Induced Oral Mucositis
• Companies Mentioned: Merck & Co Inc.; Amgen Inc.; Mundipharma International Limited; Swedish Orphan Biovitrum; EUSA Pharma; Galera Therapeutics Inc.; Enzychem Lifesciences Corporation; Oragenics Inc.; Soligenix Inc.; Jaguar Health Inc.; Monopar Therapeutics Inc.; EpicentRx; BrainCool; Cellceutix Corporation; GlycoMira Therapeutics Inc.; Innovation Pharmaceuticals Inc.; Allander Biotechnologies; Aurora BioScience; Solasia Pharma KK; NeoMedLight; MuReva (Lumitex); Prothex Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.